Status In progress
Process STA
ID number 885

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Shire
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Patients On Intravenous & Nasogastric Nutrition Therapy
  Short Bowel Survivors & Friends
Professional groups Lennard Jones Intestinal Failure Unit, St Marks Hospital
  Royal College of Physicians


Comparator companies Accord Healthcare (cimetidine, omeprazole, ranitidine) (not participating)
  Allergan (lansoprazole, omeprazole) (not participating)
  Alliance pharmaceuticals (ranitidine) (not participating)
  AstraZeneca (omeprazole) (not participating)
  Aurobindo Pharma (ranitidine) (not participating)
  Bristol Laboratories (ranitidine) (not participating)
  Chugai Pharma (sucralfate) (not participating)
  Concordia International (ranitidine) (not participating)
  Dexcel Pharma (omeprazole) (not participating)
  Dr Reddy’s Laboratories (omeprazole) (not participating)
  GlaxoSmithKline (ranitidine) (not participating)
  Janssen-Cilag (loperamide) (not participating)
  Lupin (lansoprazole) (not participating)
  McNeil Products (loperamide) (not participating)
  Omega Pharma (ranitidine) (not participating)
  Pfizer (lansoprazole) (not participating)
  Ranbaxy (lansoprazole) (not participating)
  Reckitt Benckiser Healthcare (loperamide, ranitidine) (not participating)
  Rosemont (cimetidine, ranitidine) (not participating)
  Sandoz (omeprazole) (not participating)
  SSL International (loperamide) (not participating)
  The Boots Company (loperamide, omeprazole, ranitidine) (not participating)
  Wockhardt UK (loperamide) (not participating)
  Zentiva (lansoprazole, loperamide, omeprazole) (not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
31 January 2018 Following the second Appraisal Committee on 4 January this appraisal has been suspended because the company has provided more information that needs to be considered by NICE, and because some technical issues need to be explored in more detail. We will update you on the revised timelines as soon as possible.
04 January 2018 Committee meeting: 2
13 November 2017 - 04 December 2017 Appraisal consultation
18 October 2017 Committee meeting: 1
26 May 2017 Invitation to participate
01 April 2016 Draft scope documents
15 March 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance